Business Wire

NY-CELONIS

Share
Celonis Announces Acquisition of Process Analytics Factory (PAF) to Enable Execution Management Everywhere

Celonis , the global leader in execution management, announced the acquisition of Process Analytics Factory GmbH (PAF), a leading provider of process mining insights for Microsoft Power BI. This acquisition will enable millions of Microsoft Power Platform users to utilize Celonis’ market leading Execution Management System (EMS) for process mining, automation, and collaboration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005245/en/

The acquisition of PAF is part of Celonis’ strategy to enable companies everywhere and in all industries to use process mining within the Celonis EMS to reveal and fix process inefficiencies. Celonis is committed to empowering users of the top automation, collaboration, and workflow platforms to run their businesses using Celonis’ unique process insights and intelligent, targeted actions.

The PAFnow process mining product is completely integrated into Microsoft Power BI and Microsoft Office 365 for the analysis, visualization and optimization of almost any process. 97 percent of the Fortune 500, and over 260,000 companies globally, use Microsoft Power BI.

The Celonis EMS combines, in one integrated cloud platform, real-time data, process intelligence, and targeted action to impact top, bottom, and greenline business performance at speed. Customers looking to get full clarity on how their business processes are running - whether across supply chains, shared service centers, or system landscapes - can now benefit from the unique and advanced capabilities of the Celonis EMS within their familiar Microsoft environments.

Maximilian Gerbert, project lead at Mercedes-Benz Management Consulting, said: “We - the Digital Accelerator of Mercedes-Benz - are a data-driven department with a business intelligence strategy built over years, but once we brought process mining into our BI infrastructure we were able to see the full picture and identify process inefficiencies throughout our company that we never could before. When supply chain issues come up, we use insights from process mining within BI to pinpoint the bottlenecks and take action to fix them — before they impact our cash flow and our customer experience. We are excited by the news of the Celonis acquisition and the ability to leverage the powerful capabilities of the Celonis EMS within our Microsoft environment.”

"It’s great to see Celonis and PAF join forces,” said Linus Linder, Head of IT at Muller - Die lila Logistik Service GmbH. “Now we can benefit from the real-time data, process intelligence, and targeted action in the Celonis EMS within our familiar Microsoft Power BI environment."

The rapid adoption of the Celonis EMS comes on the heels of a generational shift to use process insights and intelligence to change how businesses are run.

According to Gartner® the market for hyper-automation software will reach nearly $860 billion by 20251 . But many businesses do not maximize the value of their digital investments because they lack insight into outdated processes holding back business operations. According to a Forrester report commissioned by Celonis, process mining has hit an inflection point in 2022 as decision makers demand better execution by finding and fixing process inefficiencies.

“Since we started 11 years ago, the Celonis mission has always been the same - to help our customers reach the full potential of their business performance by removing process inefficiencies - and that requires Celonis to be everywhere,” said Alex Rinke, co-CEO and co-founder of Celonis. “The PAF acquisition enables the millions of users of the Microsoft Power Platform to use Celonis’ unique data and intelligent insights to power analytics, automation, and collaboration.”

“This combination leverages the strength of Celonis market leadership with the foundation that PAF has created in the Microsoft Power Platform. This allows our companies to build the bridge between the Microsoft Power Platform and the Celonis Execution Management System,” said Tobias Rother, CEO and founder of PAF. “We are thrilled to help put Celonis into the hands of such a large and fast-growing community of business leaders.”

“In our inaugural HFS SaaS XXV 2022 report we ranked Celonis as the top private SaaS company in Overall Rank, Business Value Creation, Partner Engagement, and OneOffice Alignment,” said Phil Fersht, CEO and Chief Analyst of HFS Research. “The acquisition of PAF demonstrates why Celonis is ranked alongside Microsoft, Salesforce, Amazon, Adobe, and Google for shaping the future of native automation, data, and process design. Celonis is strategically moving its unique process data and intelligent insights into the world’s largest work, automation, and analytics platforms.”

"The purpose of process mining is to gain a fact-based understanding of business process variance and inefficiency to systematically improve processes to maximize performance while aligning with the overall goals of a business. Embedding process mining into common analytics platforms makes it easier for teams to work together using familiar tools,” said Maureen Fleming, Program Vice President for the IDC Intelligent Process Automation Market Research and Advisory Service.

The PAFnow software capabilities will debut in Celonis Experiences at Celonis World Tour 2022 . Celonis Experiences will showcase how customers can seamlessly integrate Celonis EMS with Microsoft Power BI reporting, collaborate with Microsoft Teams, and trigger flows in Microsoft Power Automate.

About Celonis

Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of implementations in global customers and is headquartered in Munich, Germany and New York City, USA with 20 offices worldwide.

© 2022 Celonis SE. All rights reserved. Celonis, Execution Management System, EMS and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.

1 Gartner, Forecast Analysis: Hyperautomation of Enablement Software, Worldwide, Cathy Tornbohm, Fabrizio Biscotti, Rachel Chippendale, March 22, 2021.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 12:00:00 CEST | Press release

IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 11:12:00 CEST | Press release

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression of progressive supranuclear palsy (PSP)The study is being conducted across 44 centers in the European Union, the United Kingdom, and the United StatesThe study reinforces Ferrer’s commitment to researching and developing transformative therapeutic solutions for people with rare neurological diseases Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 10:51:00 CEST | Press release

Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon

Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 10:00:00 CEST | Press release

Investment in European infrastructure strengthens Impartner’s EMEA operations and commitment to data security and regional growth Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azu

NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 10:00:00 CEST | Press release

NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye